Quality measures are important tools for monitoring and improving cancer care because they can standardize the delivery of care among healthcare providers and various healthcare organizations. Quality measures also may be used to highlight opportunities for improvement in performance and outcomes among individual providers, to inform public reporting about the cost-to-benefit ratio, or value, of care among competing plans or providers. Correspondingly, measures are used to support ‘value-based’ payment models that reward healthcare providers for delivering high quality care and reducing healthcare cost. The availability of meaningful quality measures allows these value-based payment programs to better assess the quality of healthcare delivery in the context of costs, and to protect against possible unintended consequences where quality may be compromised to reduce spending by program participants. In an environment characterized by a rapidly shifting immunotherapeutic landscape and lack of associated long-term outcome data, defining quality measures for the delivery of cancer immunotherapy is a high-unmet medical need. To identify measure concepts that can be used to bridge gaps in value-based models, the Society for Immunotherapy of Cancer (SITC) analyzed the cancer quality measure landscape, identified, and prioritized cancer immunotherapy quality measure concepts that are priority areas for development. We will review the process that SITC implemented to develop quality care measures as it relates to cancer immunotherapy as a model system for adoption.